The pharmaceutical field is in full expansion, the production and values chains are undergoing changes that require the different actors to adapt.
The pharmaceutical groups modify progressively their business model and focus their efforts on R&D by outsourcing one part of the API/HPAPI production to partners and/or CMO (Contract Manufacturing Organisation).
Their priorities are:
De Dietrich Process Systems solutions meet perfectly the pharmaceuticals companies new expectations.
1. In terms of material with the DD3009 enamel and its top class properties:
Easy cleaning thanks to a very smooth roughness of 0.03 (0.8 for electropolished stainless steel), anti-adhesive properties, compliance with FDA requirements and without any risk of contamination of the final product.
Moreover, the DD3009 enamel benefits from a high corrosion resistance (acid, alkalin) and can be used across a wide range of temperatures and pressures
2. In terms of reactors design and functionality:
On De Dietrich Process Systems reactors dedicated to pharmaceuticals industries (pharma reactor), the advantages are very significant:
Reduction of the dead zone area thanks to specific design:
Integration of instrumentation and functionalities allowing a very good media quality:
In addition to the equipment, CIP studies (Cleaning In Place) can be carried out by us, to guarantee that the spray-balls cover properly the reactor’s walls and to identify the shadow areas for a better control and cleaning.
These studies allow customers to define a quality and reproducible cycle, optimising the production steps and allowing to plan precisely the shutdown.
Therefore, De Dietrich Process Systems solutions and products aren’t only dedicated to chemical applications but are also well suited to meet pharmaceutical manufacturing standards.